Global Osteosarcoma Drug Market, By Types (Central Tumor and Surface Tumor), Treatment (Surgery and Medication), Mechanism of Action (Topo Isomerase Inhibitor, RNA Synthesis Inhibitor, Dihydrofolic Acid Reductase Inhibitor, Monoclonal Antibody and Others), Drugs (Doxorubicin, Methotrexate, Dactinomycin, Denosumab, Cyclophosphamide and Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Osteosarcoma Drug Market Analysis and Size
The market is forecasted to have a rising growth with the growing incidence of metabolic disorders and chronic kidney diseases (CDKs). It is expected that most people above 50 years are suffering from osteoporosis while some of them could be at the risk of developing the bone disease. Osteosarcoma is the most common type of cancer and it typically occurs in children and young adults. The urgent rise in the need for new treatment of rare cancers such as osteosarcoma will provide potential opportunities for the growth of the market in the upcoming years.
Data Bridge Market Research analyses a growth rate in the osteosarcoma drug market in the forecast period 2023-2030. The expected CAGR of osteosarcoma drug market is tend to be around 5.50% in the mentioned forecast period. The market value is USD 1.2 billion in 2022, and it would grow up to USD 1.84 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Osteosarcoma Drug Market Scope and Market Segmentation
2023 to 2029
2021 (Customizable to 2015 - 2020)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Types (Central Tumor and Surface Tumor), Treatment (Surgery and Medication), Mechanism of Action (Topo Isomerase Inhibitor, RNA Synthesis Inhibitor, Dihydrofolic Acid Reductase Inhibitor, Monoclonal Antibody and Others), Drugs (Doxorubicin, Methotrexate, Dactinomycin, Denosumab, Cyclophosphamide and Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Lilly (U.S.), AstraZeneca (U.K.), Amgen Inc. (U.S.), Bellicum Phamaceuticals, Inc (U.S.), Incyte (U.S.)
Osteosarcoma treatment mainly involves surgery and chemotherapy. Radiation therapy is also used in certain situations. The osteosarcoma drugs are used to treat patients having the condition of bone cancer. Osteosarcoma can also referred to as a common type of bone cancer that is established in the cells that cause bones formation. In very exceptional situations, the osteosarcoma happens in the soft tissue outside the bones. Generally, it largely happens in young adults, teenagers, and older adult population.
Osteosarcoma Drug Market Dynamics
- Increased Launches of Drugs
The growing launches of new drugs and regulatory approvals for bone cancer are anticipated to drive the market growth during the forecast period 2023-2030. For instance, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter in May 2020, from the U.S. FDA regarding the Biologics License Application (BLA) for idecabtagene vicleucel for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2020. Thus, this factor is expected to boost the market growth.
- Increasing Drug Approvals By Several Market Players
More and more drug approvals lead to the increase in the market growth. For instance, the FDA approved a monoclonal antibody named Denosumab in 2010 for treating patients suffering from postmenopausal women at high risk of fractures. Furthermore, Teriparatide is a synthetic parathyroid hormone form and the only FDA-approved anabolic. Phosphate binding agents and dialysis are also widely used in the treatment of hyperphosphatemia. This boost the market growth.
- Increased Demand of Chemotherapy
The rising demand for chemotherapy is boosting the growth of the market. For instance, EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, and Pfizer Inc. announced that the U.S. Food and Drug Administration had approved the supplemental Biologics License Application (sBLA) for BAVENCIO (avelumab) in April 2020, for the treatment of patients having locally advanced or metastatic urothelial carcinoma (UC). Thus, this factor helps in the growth of the market.
- Increasing Strategic Alliances between Market Players
Major market players in market are focusing on inorganic growth strategies, which is anticipated to drive the market growth during the forecast period 2023-2030. For instance, Amgen is one of the world's leading biotechnology companies mainly focusing on the clinical development and commercialization of MP0310 by entering into a strategic collaboration with Molecular Partners in December 2018. MP0310 is a preclinical molecule which is designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells and co-stimulating T cells via 4-1BB. Thus, this factor boosts the market growth.
- Risk of Side-Effects
The numerous side-effects that are related with osteosarcoma drug could limit the growth of the global osteosarcoma drug market during the forecast period. Side-effects such as dyspepsia, headache, and to some extent, myalgia, flushing, low-back pain, and rhinitis are visible with the use of osteosarcoma drug. Thus, this effects hamper the market growth.
- Lack of Knowledge and Awareness about Osteosarcoma
The lack of expertise and knowledge associated with bone cancer in some low- and middle-income countries such as Kenya and India hamper the market growth. Also, the awareness about osteosarcoma is not much in these countries. Hence the treatment availability is also less. Thus, this factor hampers the market growth.
This osteosarcoma drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteosarcoma drug contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Osteosarcoma Drug Market Scope
The osteosarcoma drug market is segmented on the basis of types, treatment, mechanism of action, drugs, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Central Tumor
- Surface Tumor
Mechanism of Action
- Topo Isomerase Inhibitor
- RNA Synthesis Inhibitor
- Dihydrofolic Acid Reductase Inhibitor
- Monoclonal Antibody
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Osteosarcoma Drug Market Regional Analysis/Insights
The osteosarcoma drug market is analyzed and market size insights and trends are provided by types, treatment, mechanism of action, drugs, route of administration, end users and distribution channel as referenced above.
The major countries covered in the osteosarcoma drug market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for osteosarcoma drug market throughout the forecasted period because of the increased new research and developments on osteosarcoma drug. Also, the incidence of well settled healthcare infrastructure is also increasing the market growth.
North America dominates the market due to the presence of major key manufacturers of the product is high and, growing research and development activities. The rise in the occurrence of bone cancer will boost the growth of the osteosarcoma drug market in the region during the forecast period 2023-2030.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Osteosarcoma Drug Market Share Analysis
The osteosarcoma drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteosarcoma drug market.
Key players operating in the osteosarcoma drug market include:
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland.)
- Hikma Pharmaceuticals plc (U.K.)
- Aurobindo Pharma (India)
- Melinta Therapeutics, Inc (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Bellicum Phamaceuticals, Inc (U.S.)
- Incyte (U.S.)